

Cancer Treatment Compound Derived from Callyspongia

A synthesized compound derived from marine sponges provides a novel macrocycle for optimizing pharmaceutical properties in various cancer treatments.

Marine sponges of the genus Callyspongia have proven to be rich sources of natural products that display cytotoxic activity. These cytotoxic activities were isolated to callyazepin, a nitrogenous macrocycle that showed cell cytotoxicity and inhibition of lymphoma cells. Synthesis of the callyspongiolide could aid in structural determination and biological studies.

Researchers at Purdue University have synthesized a compound derived from the Callyspongia's cytotoxic activity macrocycle that treats various forms of cancer. The synthesis has allowed the preparation of various structural derivatives for optimization of pharmaceutical properties.

Advantages:

- Callyspongia is a natural source of cytotoxic activity
- Cancer treatment and symptom treatment
- Potential to provide relief to cancer patients

Potential Applications:

- Pharmaceuticals
- Cancer treatment
- Treatment of cancer symptoms

TRL: 3

Intellectual Property:

Provisional-Patent, 2016-05-27, United States | DIV-Patent, 2017-05-26, Japan | NATL-Patent, 2017-05-26, China | NATL-Patent, 2017-05-26,

Technology ID
2016-GHOS-67560

Category

Pharmaceuticals/Other
Pharmaceuticals/Pharmaceutical
Manufacturing & Methods

Authors

Arun K Ghosh
Luke Kassekert

Further information

Joe Kasper
JKKasper@prf.org

Nathan Smith
nesmith@prf.org

View online



European Patent | DIV-Patent, 2017-05-26, China | NATL-Patent, 2017-05-26,
Republic of Korea | NATL-Patent, 2017-05-26, Hong Kong | NATL-Patent,
2017-05-26, Japan | NATL-Patent, 2017-05-26, Canada | PCT-Patent, 2017-
05-26, WO | NATL-Patent, 2018-11-26, United States | EP-Patent, N/A,
Switzerland | EP-Patent, N/A, United Kingdom | EP-Patent, N/A, Germany |
EP-Patent, N/A, Italy | EP-Patent, N/A, France